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Background: The screening and treatment of latent tuberculosis (TB) infection reduces the risk of progression to
active disease and is currently recommended for HIV-infected patients. The aim of this study is to evaluate, in a low
TB incidence setting, the potential contribution of an interferon-gamma release assay in response to the mycobacterial
latency antigen Heparin-Binding Haemagglutinin (HBHA-IGRA), to the detection of Mycobacterium tuberculosis infection
in HIV-infected patients.
Methods: Treatment-naïve HIV-infected adults were recruited from 4 Brussels-based hospitals. Subjects underwent
screening for latent TB using the HBHA-IGRA in parallel to a classical method consisting of medical history, chest
X-ray, tuberculin skin test (TST) and QuantiFERON®-TB Gold In-Tube (QFT-GIT). Prospective clinical and biological
follow-up ensued, with repeated testing with HBHA-IGRA. A group of HIV-infected patients with clinical suspicion of active
TB was also recruited and tested with the HBHA-IGRA. Multiplex analysis was performed on the culture supernatants of
this in-house assay to identify test read-outs alternative to interferon-gamma that could increase the sensitivity of the test.
Results: Among 48 candidates enrolled for screening, 9 were identified with latent TB by TST and/or QFT-GIT results.
Four of these 9 patients and an additional 3 screened positive with the HBHA-IGRA. This in-house assay identified all
the patients that were positive for the TST and showed the best concordance with the presence of a M. tuberculosis
exposure risk. During follow-up (median 14 months) no case of active TB was reported and HBHA-IGRA results remained
globally constant. Fourteen HIV-infected patients with clinical suspicion of active TB were recruited. Active TB was
confirmed for 6 of them among which 3 were HBHA-IGRA positive, each with very high interferon-gamma
concentrations. All patients for whom active TB was finally excluded, including 2 non-tubercular mycobacterial infections,
had negative HBHA-IGRA results. Multiplex analysis confirmed interferon-gamma as the best read-out.
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Conclusions: The HBHA-IGRA appears complementary to the QuantiFERON®-TB Gold In-Tube for the screening of latent
TB in HIV-infected patients. Large-scale studies are necessary to determine whether this combination offers sufficient
sensitivity to dismiss TST, as suggested by our results. Furthermore, HBHA-IGRA may help in the diagnosis work-up of
clinical suspicions of active TB.
Keywords: Active tuberculosis, Heparin-binding haemagglutinin, Human, Human immunodeficiency virus,
Interferon-gamma release assay, Latent tuberculosis, Multiplex, Mycobacterium tuberculosis, QuantiFERON®-TB
Gold In-Tube, Tuberculin skin testBackground
In HIV-infected subjects the risk of reactivation of a la-
tent tuberculosis infection (LTBI) reaches 10% per year,
and the overall risk of developing active tuberculosis
(TB) is 21 to 34 times greater than for non HIV-infected
individuals [1,2]. Although this risk decreases with treat-
ment by combination antiretroviral therapy (cART), it
still remains twice that of the general population [3].
Consequently, TB remains the main cause of death in
HIV-infected patients. In 2012, 13% of the 8.6 million
new cases of TB reported worldwide were diagnosed in
patients living with HIV and 320,000 people died of
HIV-associated TB [4]. In response to this threat, pre-
vention of TB by the screening and treatment of LTBI
in HIV-infected patients is now recommended by
international guidelines and promoted by the World
Health Organisation’s “Three I’s” strategy for TB control
(“Intensified case finding, Isoniazid preventive therapy and
TB Infection control for people living with HIV”) [4-6].
The currently available tests used for the detection
of LTBI are the tuberculin skin test (TST), the
QuantiFERON®-TB Gold In-Tube (QFT-GIT) and the
T-SPOT.TB®. The TST measures the in vivo delayed
hypersensitivity response to mycobacterial antigens con-
tained in Purified Protein Derivative (PPD). The test lacks
sensitivity, particularly in HIV-infected subjects, and has a
low specificity due to cross-reactivity with the BCG
vaccine and non-tubercular mycobacteria [7,8]. The QFT-
GIT and the T-SPOT.TB® are T-cell based interferon-
gamma-release assays (IGRA) that measure respectively
the levels of Interferon-gamma (IFN-γ) released and the
number of IFN-γ-producing cells after an in vitro stimula-
tion by specific RD-1/RD-11 Mycobacterium tuberculosis
(Mtb) antigens. These two assays demonstrate a greater
specificity than TST for the diagnosis of LTBI but their
sensitivities remain insufficient [9,10]. Discordant results
between the 3 tests are frequent in HIV-infected patients,
even in low BCG vaccination settings [11], and combining
TST and an IGRA is therefore encouraged to increase the
sensitivity of screening [5,6].
Various strategies to discover superior LTBI screening
tools are being explored, including the development
of IGRA in response to alternative Mtb antigens notpresent in QFT-GIT and T-SPOT.TB®. A potential candi-
date is the Heparin-Binding Haemagglutinin (HBHA), a
methylated Mtb protein regarded as a latency antigen.
Indeed, most LTBI subjects show high levels of IFN-γ
secretion by their peripheral lymphocytes upon stimula-
tion with HBHA. The levels of IFN-γ reached are signifi-
cantly higher than those recorded both in subjects free
of Mtb infection and in patients with active TB [12,13].
An in-house IGRA based on HBHA (HBHA-IGRA) has
been shown to be a promising LTBI screening tool, both
in immune-competent adults and in haemodialysed pa-
tients [13,14]. In HIV-infected patients, the only avail-
able results concerning the IFN-γ response to HBHA
are those published by Loxton et al., who tested the
antigenic response with a whole blood assay in 4 sub-
jects living in South Africa [15]. The aim of the present
study is to evaluate, in a low TB incidence setting,
the potential contribution of the HBHA-IGRA to the
screening of LTBI in HIV-infected patients.
Methods
Ethics statement
The protocols for this study (P2011/311 and P2011/113)
received approval from the leading ethics committee
“ULB - Hôpital Erasme” (aggregation number OMO21)
and all participants signed an informed consent.
Study setting
The study was set in Belgium, a low TB incidence coun-
try of less than 10 cases/100,000 inhabitants, and more
precisely in its capital Brussels that reports a TB incidence
of 27.4/100,000 inhabitants [16]. Patient enrolment took
place between December 2011 and December 2012, and
clinical follow-up was pursued until November 2013.
Study outline
Treatment-naïve HIV-infected adults (≥18 years old)
were recruited from 4 different hospitals. Exclusion criteria
were pregnancy, breast-feeding and anti-TB treatment
within the past 6 months. The subjects enrolled underwent
LTBI screening at baseline with an HBHA-IGRA in parallel
to a classical approach consisting of medical history, chest
X-ray, TST and QFT-GIT. Prospective clinical follow-up
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LTBI treatment, initiation of cART, novel Mtb exposure
risk factors and development of active TB or TB-associated
immune reconstitution inflammatory syndrome (TB-IRIS).
The HBHA-IGRA was repeated during the first year
of follow-up at the rhythm established by the treating
physician for the evaluation of the patient’s HIV-infection
parameters.
A group of HIV-positive adults with clinical suspicion
of active TB were also recruited and tested with HBHA-
IGRA. The objective was to evaluate whether the
HBHA-IGRA results obtained in the course of active TB
differ from those obtained in LTBI. Indeed, a relative
discrimination between TB and LTBI by an HBHA-
IGRA performed on PBMC has been described in HIV
uninfected persons but whether this asset persists in
HIV-infected patients remains unknown [13]. For this
group of patients, blood was sampled for the HBHA-
IGRA prior or within 5 days of anti-TB treatment and, if
TB was confirmed, repeated after at least 1 month of
therapy. Diagnosis of TB was based either on microbio-
logical proof or high clinical suspicion with favourable
response to anti-TB treatment. When applicable, the infec-
tions were qualified as “unmasking TB-IRIS”, “paradoxal
TB-IRIS” or “ART-associated” using the International
Network for the Study of HIV-associated IRIS (INSHI)
case definitions [17]. Again, relevant clinical events arising
during treatment were documented.
For all patients CD4+ T cell counts, CD4+ percentages,
CD4+/CD8+ ratios and viral load performed within
1 month of the HBHA-IGRA were recorded at baseline
and throughout follow-up.
Finally, various chemokines and cytokines were quan-
tified by the multiplex technology in the culture super-
natants of a selection of QTF-GIT and HBHA-IGRA
with the aim of identifying complementary test read-
outs to IFN-γ.
Classical LTBI screening: medical history,
chest X-ray, TST and QFT-GIT
Medical history was taken using a questionnaire on gen-
eral epidemiological data, BCG vaccination status, risk
factors for Mtb exposure and for LTBI reactivation. The
questionnaire was completed by participating infectious
disease specialists. Chest X-ray was obtained with
postero-anterior and lateral views and interpreted in
each hospital by a local radiologist. TST was performed
by the intradermal injection of 2 units of PPD RT23
(Statens Serum Institute, Denmark) and indurations
were evaluated 72 hours later by the aforementioned in-
fectious disease specialists. The cut-off of positivity used
was a diameter of induration ≥5 mm, as is currently rec-
ommended for HIV-infected patients [6,18]. QFT-GIT
was the commercialized IGRA used (Qiagen, Venlo, TheNetherlands). Analysis and interpretation was performed
by the laboratory of Immunobiology of the Hôpital
Erasme, following the manufacturer’s instructions. Blood
was sampled for QFT-GIT, as for the in-house HBHA-
IGRA, on the first day of TST or exceptionally within
3 days to avoid a boosting effect of the PPD injection [19].
HBHA-IGRA
The HBHA-IGRA was performed as previously de-
scribed [20]. Briefly, peripheral blood mononuclear cells
(PBMC) were purified from fresh blood samples. Four
million cells were then distributed equally into 4 tubes
to allow simultaneous stimulation with (1) 2 μg/ml of
native HBHA (purified as previously described [21]),
(2) 4 μg/ml of PPD (Statens serum institute, Copenhagen,
Denmark) as a signal of previous mycobacterial exposure,
(3) 0.5 μg/ml of superantigen SEB (Sigma Aldrich, Bornem,
Belgium) as a positive control or (4) medium alone as a
negative control. In each tube, 1 ng/ml of Interleukin-7
(R&D Systems Europe, Abington, UK) was added, a tech-
nique that has recently shown to increase the sensitivity of
the assay without modifying its specificity [20]. The stimu-
lated cells were then incubated in a RPMI 1640 medium
(Lonza, Verviers, Belgium) enriched as detailed elsewhere
[22]. Culture supernatants were harvested after 24 hours
and stored at −20 C. The IFN-γ concentrations in the su-
pernatants were measured by classical sandwich ELISA
(Elisa IFN-γ Cytoset, Life technologies, Gent, Belgium).
When detectable, the concentrations obtained in the
antigen-free condition were subtracted from those ob-
tained with antigen stimulation in order to measure the
antigen-specific response. Tests with IFN-γ concentrations
below 100 pg/ml in response to SEB were considered inde-
terminate. The cut-offs applied for the IFN-γ concentra-
tions in response to PPD and HBHA were 200 pg/ml and
50 pg/ml, respectively, as has been defined in immune-
competent adults. Positive responses to both PPD and
HBHA were necessary for the assay to be considered posi-
tive, as this interpretation method has been previously vali-
dated and increases the specificity of the test [20].
Multiplex analysis
For selected subjects, a panel of analytes (IL-6, IL-8, IP-
10, MCP-1, MIP-1β, GM-CSF, IL-10, IL-13, IL-17A, IL-
2, TNF-α and sCD40L) were quantified in the culture
supernatants of their HBHA-IGRA (PPD-, HBHA- and
non-stimulated tubes) and QFT-GIT tests (TB Antigen
tube and Nil tube) using MILLIPLEX® MAG panels
(Merckx Millipore, Brussels, Belgium) following the man-
ufacturers’ instructions. However, culture supernatants
were initially diluted using dilution factors specific to
each analyte in order to obtain concentrations lying
within an interpretable range. Results were analysed with a
Bio-Plex® MAGPIX™ Multiplex reader, Bio-Plex Manager™
Table 1 Baseline characteristics of the LTBI screening
candidates
Demographics Number (n = 48)





Sub Saharan 22 (46%)
Caucasian 18 (38%)
North African 3 (6%)
Asian 3 (6%)
South American 2 (4%)
Mtb exposure risk factors
Presence of at least one major Mtb exposure
risk factor
23 (48%)
Born in high incidence countrya 22 (46%)
Arrival in low incidence country≤ 2 years 4 (8%)b
Self-reported close contact with a case of TB 1
Close contact with a case of sputum positive TB 1
Otherc 5 (10%)
Visitors of endemic countriesd 14 (29%)
LTBI reactivation risk factors




Body mass index < 18,5 2 (4%)
Renal insufficiency +/− dialysis 1
Solid tumor 1
Alcoholism 1
Self-reported BCG vaccination status
Vaccinated 16 (33%)





Seroconversion ≤ 2 years 9 (19%)e
CD4+ T-cell count; median [range] 517 [1–1065]
Viral load; median [range] 23242 [<40-1.107]f
Units: Age (years); CD4+ T-cell count (cells/mm3); viral load (copies/ml).
a>100 cases of TB/ 100000 inhabitants.
bRepresents 17% of those born in a high incidence country.
cProfessional risk, previous incarceration, asylum seeker, homeless.
dConcerns the patients born in low incidence country.
eDate of HIV seroconversion unknown for 40% of the enrolled subject.s
fThe patient with an undetectable viral load is an elite controller (HIV-2 infected).
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RAD laboratories, Nazareth Eke, Belgium). If detectable,
the analyte concentrations obtained in the antigen-free
conditions were subtracted from those obtained with anti-
gen stimulation. To allow statistical analysis with continu-
ous variables, the concentrations below the detection limit
were allocated an arbitrary value of 10 pg/ml, representing
an undetectable response, whilst results exceeding the as-
say’s upper limit of detection were attributed the concen-
tration corresponding to this limit.
Statistical methods
Results were analyzed using GraphPad Prism version
5.04 (GraphPad Software, La Jolla California USA, www.
graphpad.com). The Mann–Whitney U test and the
Kruskall-Wallis test were applied to compare continuous
variables between groups. Univariate analysis was per-
formed by Fisher’s exact test and odds ratios for categor-
ical variables. Chi-squared test for trend was applied for
ordinal variables. Correlation between continuous vari-
ables was assessed using Pearson's product moment co-
efficient. A p-value <0.05 was considered significant.
Results
Population characteristics
Forty-eight treatment-naïve HIV-infected patients were
enrolled between December 2011 and December 2012.
Demographic characteristics, Mtb exposure and LTBI re-
activation risk factors, as well as BCG vaccination status
and HIV-infection characteristics at baseline are summa-
rized in Table 1.
Three patients were lost to follow-up. For the remaining
patients, the median clinical follow up time reached
418 days, ranging from 6 to 23 months. cART was initi-
ated in 26 patients at various time points, 15 immediately
after enrolment. The median increase in CD4+ T-cell
counts between baseline values and the final measurement
was 113 cells/mm3 in treated patients, and 6 patients
showed an increase of >200 cells/mm3. Isoniazid prophy-
lactic treatment was offered to 3 patients, but, due to non-
compliance, completed only by one. Six patients travelled
to countries of moderate to high TB incidence (>40 cases/
100,000 inhabitants) during follow-up, but no other major
risk factor for Mtb exposure was recorded. No patients de-
veloped active TB.
Fourteen HIV patients with suspected TB were en-
rolled and are discussed separately in the corresponding
paragraph.
LTBI screening results
Amongst the 48 HIV-infected patients that underwent a
screen for LTBI, 23 had at least one major Mtb exposure
risk factor revealed by the questionnaire (Table 1). The
item “visitors of endemic countries” of the questionnaire
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in terms of Mtb exposure risk (duration, conditions etc.)
and was therefore classified separately. Seven patients
had an LTBI reactivation risk factor in addition to HIV-
infection.
Chest X-ray was performed in 46 patients and was
found suspicious in 3, with bilateral apical infiltrates in
one, right lobe apical infiltrates with fibrotic scars and
possible calcified mediastinal lymph node in the second
and bi-apical fibrotic scarring with retraction for the
third. Complementary Computed Tomography Scan
(CT-scan) of the chest was performed in the first 2 pa-
tients and the initially described abnormalities were not
confirmed. All 3 patients had negative results for the
QFT-GIT, TST and HBHA-IGRA.
TST results were available for 46 individuals as 2
patients did not return for TST result reading, whilst
QFT-GIT and HBHA-IGRA were available for all. HBHA-
IGRA, as detailed in the methods, combines PPD- and
HBHA-induced IFN-γ responses. Results of this test in re-
lation to TST and QFT-GIT results are shown in Figure 1.
At baseline, TST was positive for 4 of the screened subjects
(all with an induration diameter ≥10 mm), among which 3
had a concomitant positive QFT-GIT (all with an antigen
response >2 IU/ml), and all 4 were positive with the
HBHA-IGRA. These 4 patients had reported Mtb exposure
risks and their respective CD4+ T-cell counts went from 98
to 912 cells/mm3.Figure 1 LTBI screening in treatment-naïve HIV-infected patients: rela
treatment naïve HIV-infected subjects underwent screening for latent tubercu
HBHA-IGRA results were interpretable for 43 subjects. The test measures both
200 pg/ml and 50 pg/ml respectively for the assay to be considered positive.
the graph represents the results of an individual. The format of the point (blac
the TST and QFT-GIT results obtained for the given individual, as indicated in
had undetectable IFN-γ levels in response to both PPD and HBHA, including 4Five patients tested positive only with the QFT-GIT,
with antigen responses ranging from 0.82 to 1.98 IU/ml.
All these patients had CD4+ T-cell counts above 450
cells/mm3. Only 2 had a clear Mtb exposure risk.
The HBHA-IGRA detected 3 additional patients, one
of whom had an indeterminate QFT-GIT result due to
an excessive value for the negative control. All 3 subjects
were born and lived for more than 20 years in countries
with TB incidence above 40 cases/100,000 inhabitants
[23], compatible with Mtb exposure and potential LTBI.
Their CD4+ T-cell counts at the time of screening were
equal or above 450 cells/mm3. Of note, for 5 patients
out of the 48 screened, the HBHA-IGRA was indeter-
minate, one due to a technical error and the 3 others for
absence of IFN-γ responses to the positive control.
As shown in Figure 1, two subjects had IFN-γ re-
sponses to PPD (above the 200 pg/ml cut-off ) but not to
HBHA, and all other latent tuberculosis tests negative.
These results may be caused by previous exposure to
non-tubercular mycobacteria (both grew up in sub-
Saharan Africa) or previous BCG-vaccination (recorded
in at least one). Inversely, one patient had an IFN-γ re-
sponse to HBHA but not to PPD, although this result
was probably an error as it was no longer found upon
repetition of the assay. As expected, all TST positive
patients showed high IFN-γ responses to PPD. In con-
trary, and for reasons unclear, the 5 subjects that had
a positive QFT-GIT but negative TST and negativetion between HBHA-IGRA, QFT-GIT and TST result. Forty-eight
losis with 3 different immunological tools: TST, QFT-GIT and HBHA-IGRA.
IFN-γ responses to PPD and to HBHA that must be above or equal to
These cut-offs are represented in the graph as dotted lines. Each point on
k square, black dot, white triangle or black and white square) represents
the legend of the graph. As shown in the magnified square, 26 patients
that had QFT-GIT positive tests.
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60 pg/ml.
HBHA-IGRA was repeated at an average frequency of
3 per subject over a median period of 7 months (not re-
peated in 6 patients and follow-up interrupted in one
patient who became pregnant). The majority of patients
had stable responses (82%). Four patients had variable
test results over time. An additional 3 with an initially
negative HBHA-IGRA developed persistently positive
tests during follow-up despite no new Mtb exposure risk
factor. One of these patients had a positive QFT-GIT at
baseline (antigen response of 0.82 IU/ml) and another
had a favourable response to cART with an increase in
CD4+ T-cell counts from 457 to 641 cells/mm3 and
normalization of his CD4+/CD8+ ratio at the time of test
conversion.
Effect of Mtb exposure risk, BCG vaccination status and HIV
infection parameters on the LTBI screening test results
A non-random association between baseline test results
and selected variables (Mtb exposure risk factor, BCG
vaccination, CD4+ T-cell count and viral load) was inves-
tigated. The results are shown in Table 2. A significant
association with Mtb exposure risk was shown for
HBHA-IGRA (p = 0.0353) but not for QFT-GIT. The
significance of the association between Mtb exposure
risk and TST positivity was inconclusive, as the Fisher’s
exact test results disagreed with the confidence interval
for the odds ratio (a phenomenon that may be caused by
the different handling of two-sided inference from asym-
metric sampling distributions by these two tests [24]).
The same result was found between BCG vaccination
and HBHA-IGRA outcome. Furthermore, the variables
“BCG vaccination” and “Mtb exposure risk factor” were
significantly associated (p = 0.0002). A linear trend was
present between QFT-GIT and viral load levels (a greater
number of positive results occurring in patients with
lower viral loads), but no trend was detected between
the different screening tests and CD4+ T-cell counts.
We next assessed whether HIV-infection parameters
(CD4+ T-cell counts, CD4+ percentages, CD4+/CD8+ TTable 2 Factors associated with positive LTBI screening test r
TST QF
p OR [CI 95%]) p
Mtb exposure 0.0455 11.8 [0.6-232] 0.4
BCG 0.2273 6.0 [0.2-136] 1
CD4+ T-cell count 0.8773 NA 0.7
Viral load 0.1844 NA 0.0
A non-random association between positive test results and 1) the presence of an M
4) viral loads was assessed for the TST, the QFT-GIT and the HBHA-IGRA. Fisher’s exac
for the dichotomous variables (presence or not of an Mtb exposure risk factor and BCG
viral loads organized into ordinal variables (CD4+ T-cell counts <50; 50–199; 200–499, >5
Significant p values are in bold type (p < 0.05).cell ratios and viral loads) were significant predictor var-
iables of the PPD- and HBHA-induced IFN-γ levels, as
shown in Table 3. This was the case for the CD4+ T cell
percentages and the CD4+/CD8+ T cell ratios with
regards to the levels of PPD-induced IFN-γ. Notably in-
determinate results, whether for QFT-GIT or HBHA-
IGRA, were not systematically associated to advanced
immune-depression, nor extremely high viral loads, as
only one of the 5 patients concerned had a CD4+ T-cell
count <500 cells/mm3 (280 cells/mm3) and a viral load
above 10,000 copies/ml.
HBHA-IGRA results in patients with active TB
Active TB was confirmed for 6 of the 14 HIV-infected
patients enrolled with a clinical suspicion of the disease.
For these subjects, demographics, HIV parameters and
clinical presentation are summarized in Table 4. At base-
line, 3 of these patients were HBHA-IGRA responders,
all with very high levels of IFN-γ release in response to
both PPD and HBHA, as illustrated in Figure 2. HBHA-
IGRA was re-tested after at least 1 month of anti-TB
treatment (+/− cART) in 4 of the HIV/TB confirmed cases
(in 2 HBHA-IGRA responders and 2 non-responders).
IFN-γ responses to HBHA persisted for the 2 responders
and, at various time points of treatment, converted in the 2
initially non-responders. Two patients developed paradoxal
TB-IRIS during treatment but no association was found
with baseline HBHA-IGRA response.
Multiplex analysis
The cytokine/chemokine profiles of 11 subjects with a
positive LTBI screening, 8 subjects with a negative LTBI
screening and the 6 confirmed active TB subjects were
evaluated and compared. A positive LTBI screening was
defined as the presence of at least one positive immuno-
logical test (TST, QFT-GIT or HBHA-IGRA), and a
negative LTBI screening was defined as all 3 tests being
negative and absence of any Mtb exposure risk factor.
The results are shown in Figure 3. The levels of IL-10
measured in the HBHA-stimulated culture supernatant
were statistically higher for the active TB patients whenesults
T-GIT HBHA-IGRA
OR [CI 95%] p OR [CI 95%]
455 2.2 [0.5-10.3] 0.0353 9.9 [1.1-90.7]
0.7 [0.1-5.0] 0.0318 15 [0.7-307]
777 NA 0.6021 NA
261 NA 0.0752 NA
tb exposure risk factor, 2) BCG vaccination status, 3) CD4+ T-cell counts and
t test and odds ratio (OR) with a 95% confidence interval (CI 95%) was applied
vaccination status). Chi-squared test for trend was used for CD4+ T-cell counts and
00 cell/mm3 and viral loads <40, 40–10000; 10000–100000; >100000 copies/ml).
Table 3 Effect of HIV on PPD and HBHA induced IFN-γ levels
IFN-γ conc. in response to PPD-stimulation IFN-γ conc. in response to HBHA-stimulation
n p r n p r
CD4+ T-cell count 43 0.1499 0.2261 42 0.9029 −0.0192
CD4+ % 42 0.0034 0.4473 41 0.5827 0.0873
CD4+/CD8+ ratio 43 <0.0001 0.8586 42 0.4265 0.1245
Viral load 41 0.5777 −0.0896 41 0.4643 −0.1175
Pearson correlation was used to measure the association between PPD- or HBHA-induced IFN-γ responses and four different predictor variables associated with
HIV-infection severity: absolute CD4+ T-cell counts, CD4+ percentages (%), CD4+/CD8+ ratios and viral loads. Significant p values are in bold type (p < 0.05).
conc = concentration; n = number of tests; r = pearson's product moment coefficient.
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ever, only two of the 6 active TB subjects had IL-10
levels that reached twice the concentrations found in
non-stimulated conditions. For these 2 patients, higher
analyte concentrations were found for the majority of
the cytokines/chemokines measured. The increased level
of IL-10 noted in active TB patients was therefore not
specific and probably a reflection of the general immune
activation induced by the disease.
When we focused on the HBHA-IGRA negative/QFT-
GIT positive subjects, IL-6 concentrations exceeded
100 pg/ml in the PPD-stimulated culture supernatants forTable 4 Characteristics of the HIV subjects with active
tuberculosis
Subject Demographics Baseline HIV
parameters
Clinical presentation
1 47y CD4: 68 (6%) Unmasking miliary
TB-IRISCaucasian VL: not tested
cART: yes
2 42y CD4:124 (14%) Miliary TB
Sub saharan VL: 712000
cART: no
3 28y CD4: 26 (6%) Miliary TB
Sub saharan VL: 8070000
cART: no
4 38y CD4: 141 (35%) Pulmonary TB
Sub saharan VL < 40
cART: yes
5 38y CD4: 25 (5%) Pulmonary and
ganglionary TBSub saharan VL: 201000
cART: no
6 43y CD4: 580 (37%) ART-associated
Pleuro-pulmonary TB
Sub saharan VL <40
cART: yes
ART: antiretroviral therapy; cART: combination ART; CD4: CD4+ T cell count
cells/mm3 (percentage); TB: Tuberculosis; TB-IRIS: TB-associated immune
reconstitution inflammatory syndrome; VL: viral load (copies/ml); y: years.all 5 concerned subjects. Four of them had IP-10 concen-
trations above 100 pg/ml in the HBHA-stimulated culture
supernatants. However, the increase in sensitivity for the
HBHA-IGRA detection of LTBI obtained by the use of
these two analytes was offset by a loss in specificity: for
both analytes, 3 of the 8 subjects with a negative LTBI
screening also showed levels exceeding 100 pg/ml. Like-
wise, no analyte measured in the QFT-GIT culture super-
natants could identify the 3 patients that were only
positive for the HBHA-IGRA.Discussion
This study is the first to evaluate the use of an HBHA-
IGRA as a LTBI screening tool in HIV infected patients
living in a low TB incidence country. In this cohort of
48 treatment-naïve HIV-infected subjects, 9 were identifiedFigure 2 Comparison of the IFN-γ responses to PPD and HBHA
between TB/HIV and LTBI/HIV subjects. Overall 62 HIV-infected
patients were tested with HBHA-IGRA: 48 LTBI screening candidates
and 14 patients with clinical suspicion of active TB. At baseline, 10 of
these patients had a positive HBHA-IGRA. These 10 positive assays
are represented in the graph in terms of the IFN-γ concentrations
obtained in response to PPD (Y axis) and HBHA (X-axis) stimulations.
The test cut-offs are marked by the dotted lines. The HIV-infected
subjects from the LTBI screening group (n = 7) are represented by
dots while the HIV patients with confirmed TB are encircled and
individually represented by a triangle (n = 3).
Figure 3 Multiplex analysis of culture supernatants. A panel of cytokines and chemokines were measured in the culture supernatants of (A)
PPD-stimulated peripheral blood mononuclear cells (PBMC), (B) HBHA-stimulated PBMC and (C) the TB Antigen tube of the QFT-GIT. Median
concentrations with interquartile ranges are represented in the graph. Results between subjects with a positive LTBI screening (n = 11), subjects
with a negative LTBI screening (n = 8) and active TB patients (n = 6) were compared using Mann–Whitney U test or Kruskall-Wallis test. Significant
p values are shown.
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GIT) and a TST as is currently recommended in Europe
[6]. The HBHA-IGRA identified all the patients detected
by the TST (including a patient that was negative for QFT-
GIT) and recognized a further 3 potential LTBI cases
detected by neither the TST nor the QFT-GIT. The
HBHA-IGRA was the screening tool that showed the best
concordance with Mtb exposure risk, as was previously
found in a cohort of haemodialysed patients [14].
The test appeared reproducible, as a large majority of
patients had stable responses over time, and multi-
plex analysis confirmed IFN-γ as the best read-out out of13 chemokines/cytokines. Despite a median follow-up of
14 months, no patients developed active TB. Remarkably,
isoniazid prophylactic treatment was prescribed and
completed in only one patient after LTBI screening. This
illustrates how barriers to LTBI treatment in HIV-
infected patients go beyond the problematic of screening
tool efficiency, as has been reviewed elsewhere [25,26].
The main limitation of this study is the small number
of enrolled patients rendering the results and analysis es-
sentially descriptive. As in all LTBI screening studies, the
lack of a gold standard test complicates the interpret-
ation of results. Furthermore, the absence of development
Wyndham-Thomas et al. BMC Infectious Diseases  (2015) 15:59 Page 9 of 11of active TB amongst the individuals screened prevents the
calculation of the predictive values of the tests. Nonethe-
less, this pilot study provides support for further larger
studies assessing HBHA-IGRA as a complementary tool in
the screening for LTBI in HIV-infected patients.
Several studies, both in low- and high-income coun-
tries, have evaluated and compared the TST and the
commercialized IGRA for LTBI screening in HIV-
infected patients, as reviewed by meta-analysis in 2011
[10]. Although the tests appear to have comparable sen-
sitivities, the sensitivity of each test is negatively affected
by the immunodeficiency of the patients. Indeed, HIV-
infected persons are less likely to have a positive TST or
a positive IGRA than HIV-uninfected persons, with test
positivity being inversely correlated with the CD4+ T-cell
count. IGRA indeterminate results are also more fre-
quent in HIV-infected patients when compared with the
general population [11]. The T-SPOT.TB®, although in-
consistently reported, may have an advantage over QFT-
GIT in patients with low CD4+ T-cell counts, as the
number of PBMC exposed to the mycobacterial antigens
in the assay is standardized [9]. This is also the case with
the HBHA-IGRA. In this study, a potential negative
effect of low CD4+ T-cell counts on our in-house assay
was not seen. Moreover, during follow-up, only 1 HBHA-
IGRA test conversion following favorable immunological
response to cART was recorded. However, these results
must be interpreted with caution, as the number of sub-
jects enrolled was small and only 2 patients had a baseline
CD4+ T-cell count below 50 cells/mm3.
The HBHA-IGRA, like the commercialized IGRA, of-
fers several advantages over TST including the need of a
single visit, less reader bias and the absence of a booster
effect on serial testing [11]. The internal negative and
positive controls also represent a considerable advantage
over TST for which immunological anergy may be incor-
rectly considered as a negative result. Another essential
asset of the commercialized IGRA, QFT-GIT and T-Spot
TB®, is the absence of cross-reactivity with BCG vaccin-
ation. In the case of HBHA-IGRA, it has been shown
that BCG vaccination in infants is capable of priming
HBHA specific immune responses [27]. This is conceiv-
able as HBHA is expressed by all members of the M. tu-
berculosis complex including the attenuated BCG strain
of Mycobacterium bovis from which it is purified. How-
ever, it appears that the influence of early-childhood
BCG vaccination on HBHA-IGRA becomes negligible in
adulthood [13,21,28]. Here the question could not be
properly addressed as Mtb exposition and BCG vaccin-
ation were confounding factors and sample size was too
small to perform multivariate analysis.
In line with previous studies, discordant results
were found between TST, QFT-GIT and HBHA-IGRA
[11,13,14]. These inter-assay discordances persisted evenwhen alternative analytes to IFN-γ were measured in the
QFT-GITand HBHA-IGRA supernatants. It has been sug-
gested that different Mtb infection profiles may explain
these discrepancies. Indeed, LTBI is now considered as a
heterogeneous entity, running from quiescent bacilli to
replicating Mtb with subclinical disease [29,30]. As the
commercialized IGRA use RD-1 antigens that are secreted
by actively multiplying Mtb, the LTBI patients responding
exclusively to these assays are believed to have ongoing
Mtb replication. In contrary, as T-cell responses to HBHA
are considered as markers of latency, HBHA-IGRA exclu-
sive responders are believed to be those controlling Mtb
replication [31]. In non HIV-infected individuals, it has
been suggested that these discordances could allow the
classification of LTBI according to the potential of reacti-
vation, a quality that would help target INH prophylaxis
[31]. In HIV-infected patients, however, whether the risk
of LTBI progression to active TB is different in QFT-GIT
and/or HBHA-IGRA responders is unknown. As these pa-
tients are at high risk of developing active TB particularly
during immune-reconstitution, detecting all those with
LTBI appears essential, even those with controlled latency.
Combining the QFT-GIT and the HBHA-IGRA could be
a suitable option offering a broader detection of the LTBI
spectrum. Large-scale studies are necessary to determine
whether this combination offers sufficient sensitivity to
dismiss TST from LTBI screening in HIV-infected pa-
tients, as suggested by our results.
In non HIV-infected patients, the median IFN-γ re-
sponses of isolated PBMC to HBHA appear inferior in
patients with active TB than in subjects with LTBI, offer-
ing a relative discrimination between the two groups
[13]. The inferior IFN-γ responses in active TB is due to
the presence of regulatory T lymphocytes (Tregs) sup-
pressing T-cell responses to the antigen and to the mi-
gration of HBHA-specific lymphocytes to the sites of
infected tissue [32,33]. The HBHA-IGRA did not show
this for HIV-infected patients, possibly due a high myco-
bacterial burden or an altered function of Tregs and
chemotaxis associated with HIV infection [34,35]. Con-
sequently, like all the currently available LTBI screening
tools, the HBHA-IGRA cannot differentiate LTBI from
active TB in HIV-infected patients. As HIV-infected pa-
tients can develop pauci-symptomatic disease [36], active
TB must always be excluded before instauration of
prophylactic therapy. When analyzing in greater detail, it
appeared that the HBHA-IGRA results in the HIV-
positive subjects with active TB were dichotomous: no
IFN-γ response was detected in approximately half of
the patients, whilst extremely high responses were ob-
served for the others. Factors predicting a HBHA-IGRA
response among the HIV/active TB co-infected pa-
tients remain unidentified. Elements reflecting or caus-
ing altered immune responses, such as CD4+ T-cell
Wyndham-Thomas et al. BMC Infectious Diseases  (2015) 15:59 Page 10 of 11counts < 200 cells/mm3, CD4+ percentages < 30%, inversed
CD4+/CD8+ ratios, viral loads >100,000 copies/ml and
miliary disease, were found among responders and non-
responders. Interestingly, after the instauration of anti-TB
therapy (in association or not with cART), the responses
to HBHA-IGRA persisted in responders and appeared in
subjects with initial negative results. As treated TB sub-
jects are sometimes used as surrogates for LTBI (both
representing states of controlled Mtb infection), these re-
sults underline the HBHA-IGRA’s potential as a LTBI
diagnostic tool. Moreover all the patients with TB suspi-
cion that were ultimately disconfirmed, including 2 local-
ized non-tubercular mycobacterial infections, had negative
HBHA-IGRA. Overall, in HIV-infected patients with a
clinical suspicion of TB, it seems that a very high IFN-γ
response to HBHA-IGRA may be considered as an argu-
ment in favor of TB diagnosis. However, as for the TST
and the commercialized IGRA, a negative result does not
exclude active TB. One alternative method that may prove
interesting in clinical suspicion of TB may be an HBHA-
IGRA performed on cells from the site of disease, ra-
ther than peripheral blood mononuclear cells [32],
but this approach remains to be investigated in HIV-
infected patients.Conclusions
This study, although limited in size, offers the first glimpse
of the potential diagnostic value of HBHA-IGRA in HIV-
infected patients. The assay appears as a complementary
tool for LTBI screening, identifying cases not found with
the other tests. Future studies should examine whether the
combination of QFT-GIT and HBHA-IGRA, which can be
performed after a single blood collection, offers sufficient
LTBI screening performance to dismiss TST from LTBI
screening. In HIV-positive patients, the test could also con-
tribute to the diagnosis work-up of clinical suspicion of
TB, as high IFN-γ responses to the assay seem in favour of
the diagnosis.
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